Search clinical trials for: Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC)

Total 103 results

Chengdu CoenBiotech Co., Ltd
Beijing Friendship Hospital; Beijing Chest Hospital, Capital Medical University

Completed

Phase I Clinical Trial to Evaluate the Safety of Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC) in Healthy Adults Aged 18-65 and Patients With Pulmonary Tuberculosis

Tuberculosis

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Shenzhen Third People's Hospital; Wuhan Institute for Tuberculosis Control

Recruiting

Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above

Latent Tuberculosis Infection

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Recruiting

Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein

Latent Tuberculosis Infection

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Shanghai Public Health Clinical Center; Air Force Military Medical University... and other collaborators

Completed

Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10

Healthy
GlaxoSmithKline

Completed

Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults

Tuberculosis

Belgium
St. Petersburg Research Institute of Vaccines and...

Completed

Tolerability and Reactogenicity Trial of the Recombinant Tuberculosis Allergen in Healthy Volunteers

Tuberculosis | Skin Tests

Russian Federation
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Shanghai Public Health Clinical Center; Air Force Military Medical University... and other collaborators

Completed

Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10

Tuberculosis
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Suspended

A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)

Tuberculosis

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

A Phase Ib Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)

Tuberculosis

China
Apogenix GmbH

Completed

APG101 in Glioblastoma

Glioblastoma Multiforme

Austria, Germany
Sichuan Clover Biopharmaceuticals, Inc.

Terminated

A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis

Peritoneal Carcinomatosis

China
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions

Malignant Pleural Effusions

Australia
Sichuan Clover Biopharmaceuticals, Inc.

Completed

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites

Malignant Ascites

China
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies

Peritoneal Malignancies

Australia
CSL Behring

Completed

A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B

Hemophilia B

Bulgaria, Israel
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum; Syntonix Pharmaceuticals, Inc.

Completed

Phase I/IIa Study of FIXFc in Hemophilia B Patients

Hemophilia B

United States
Zhejiang Hisun Pharmaceutical Co. Ltd.

Unknown

Efficacy and Safety Study of Anbainuo in Chinese Patients With RA/AS in the Real World

Rheumatoid Arthritis | Ankylosing Spondylitis
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale (Elevate)

Severe Hemophilia A

United States, Australia, New Zealand
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

Hemophilia A

United States, France, Italy, Spain, Netherlands, United Kingdom, Ireland, New Zealand, Poland, Australia, Germany, Brazil, Sweden, Canada
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B (B-YOND)

Severe Hemophilia B

United States, Italy, Belgium, Australia, Brazil, Hong Kong, India, Ireland, Japan, South Africa, United Kingdom, Netherlands, Sweden, Canada, Poland, China, France, Germany
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PUPs B-LONG)

Hemophilia B

United States, Italy, Ireland, New Zealand, United Kingdom, Australia, Netherlands, Denmark, Poland, Sweden, France
Bioverativ Therapeutics Inc.

Completed

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Severe Hemophilia A

United States, United Kingdom, Australia
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Terminated

Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy

Hematologic Malignancy

China
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

Severe Hemophilia B

Sweden, United States, France, Italy, Russian Federation, United Kingdom, Germany, China, Poland, Japan, Australia, Brazil, Canada, India, South Africa, Hong Kong, Belgium
Hengenix Biotech Inc

Completed

Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects

COVID 19

United States
CSL Behring

Completed

Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B

Hemophilia B

Spain, Italy, France, Germany, Austria, Israel
Chengdu Kanghong Biotech Co., Ltd.
University of Wisconsin, Madison

Completed

A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD (PHOENIX)

Neovascular Age-related Macular Degeneration

China
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A (Kids ALONG)

Hemophilia A

United States, Poland, United Kingdom, Netherlands, South Africa, Hong Kong, Australia, Ireland
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Terminated

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes (FORWARD)

Hemophilia A | Hemophilia B

United States
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A (ASPIRE)

Hemophilia A

United States, Canada, Italy, Australia, Austria, Belgium, Brazil, France, Germany, Hong Kong, India, Ireland, Israel, Japan, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
Livzon Pharmaceutical Group Inc.
Simoon Record Pharma Information Consulting Co., Ltd.; Guangdong Center for...

Completed

Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

COVID19

China
Northwestern University
National Cancer Institute (NCI); Vasgene Therapeutics, Inc

Active, not recruiting

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Progressive Disease | Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | Metastatic Prostate Adenocarcinoma | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone | Castration-Resistant Prostate Carcinoma Refractory to Second-Generation... and other conditions

United States
Sichuan Clover Biopharmaceuticals, Inc.

Recruiting

A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)

Chemotherapy-induced Thrombocytopenia (CIT)

China
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity (COVID-19)

COVID-19 Pandemic

China
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization (COVID-19)

COVID-19 Pandemic

China
Beijing VDJBio Co., LTD.

Recruiting

Clinical Study of Recombinant Humanized CTLA-4-FC Fusion Protein Injection in Healthy Subjects

Health Volunteer

China
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B (Kids B-LONG)

Hemophilia B

United States, United Kingdom, South Africa, Netherlands, Ireland, Australia
Bioverativ Therapeutics Inc.

Completed

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, Hong Kong, Israel
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III (COVID-19)

COVID-19 Pandemic

Philippines, Indonesia, Russian Federation
Tianjin SinoBiotech Ltd.

Completed

Study on Single Administration and Dose Increment of Recombinant Human Serum Albumin/Erythrocyte Fusion Protein for Injection

Healthy Subjects

China
Livzon Pharmaceutical Group Inc.

Completed

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study (COVID-19)

COVID-19 Pandemic

Malaysia, Pakistan
Tianhong Li
National Cancer Institute (NCI); OncoImmune, Inc.

Terminated

CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study

Advanced Malignant Solid Neoplasm

United States
Huabo Biopharm Co., Ltd.

Recruiting

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Tumor, Subjects

United States, China
Livzon Pharmaceutical Group Inc.

Active, not recruiting

The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine (Omicron)

COVID-19 Pandemic

China
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (COVID-19)

COVID-19 Pandemic

China
University of Southern California
National Cancer Institute (NCI)

Withdrawn

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

Recurrent Bladder Carcinoma | Bladder Cancer Stage 0 | Bladder Cancer Stage I

United States
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China
University of Southern California
National Cancer Institute (NCI); Vasgene Therapeutics, Inc; The V Foundation...

Terminated

Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Alexion Pharmaceuticals

Completed

Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)

Hypophosphatasia (HPP)

United States, Canada
Jiangsu Gensciences lnc.

Not yet recruiting

Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A

Severe Hemophilia A

China

Search clinical trials for: Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations